All participants underwent comprehensive ophthalmic examinations, which included assessments of best-corrected visual acuity (BCVA), Goldmann applanation tonometry, a refraction test, slit-lamp biomicroscopy, gonioscopy, stereo disc photography, red-free fundus photography (EOS D60 digital camera; Canon, Utsunomiyashi, Tochigiken, Japan), central corneal thickness measurement (Orbscan II; Bausch & Lomb Surgical, Rochester, NY, USA), and axial length measurement (IOLMaster version 5; Carl Zeiss Meditec, Dublin, CA, USA). Peripapillary RNFL thickness was measured by spectral-domain OCT (Spectralis; Heidelberg Engineering, Heidelberg, Germany). Other ophthalmic examinations included standard automated perimetry (Humphrey Field Analyzer II 750, 24-2 Swedish interactive threshold algorithm; Carl Zeiss Meditec) and swept-source OCT scanning of the ONH and OCTA (DRI OCT Triton; Topcon, Tokyo, Japan). Clinical history was also taken from participants, including demographic characteristics and the presence of cold extremities, migraine, and other systemic conditions. Systolic and diastolic blood pressures (BPs) were measured using a digital automatic BP monitor (Omron HEM-770A; Omron Matsusaka Co., Ltd., Matsusaka, Japan). Mean arterial pressure (MAP) was calculated using the expression MAP = diastolic BP + 1/3 (systolic BP − diastolic BP), and mean ocular perfusion pressure (MOPP) was calculated using the equation MOPP = 2/3 (MAP − IOP) at the time of OCTA.
POAG was defined as the presence of an open iridocorneal angle, signs of glaucomatous optic nerve damage (i.e., neuroretinal rim thinning, notching, or a RNFL defect), and a glaucomatous visual field (VF) defect. A glaucomatous VF defect was defined as a defect conforming with one or more of the following criteria: (1) outside normal limits on a glaucoma hemifield test, (2) three abnormal points with a <5% probability of being normal and one abnormal point with a <1% probability by pattern deviation, or (3) a pattern standard deviation of probability <5% confirmed on two consecutive reliable tests (fixation loss rate of ≤20% and false-positive and false-negative error rates of ≤25%).
The exclusion criteria were eyes with a BCVA worse than 20/40, a spherical equivalent of <−8.0 diopters (D) or >+3.0 D, a cylinder correction of <−3.0 D or >+3.0 D, a history of intraocular surgery with the exception of uneventful cataract surgery, and retinal (e.g., diabetic retinopathy, retinal vessel occlusion, or retinoschisis) or neurological diseases (e.g., pituitary tumor).
Those patients included in the IGPS who underwent trabeculectomy and for whom pre- and postoperative OCTA results were available were included in the present study. Indications for trabeculectomy were IOP deemed to be associated with a high risk of progression, or glaucomatous progression of the VF or optic disc despite taking the maximum tolerated medications. All ocular hypotensive medications were continued up to the time of surgery. Eyes with signs of hypotony, maculopathy, or disc edema after surgery were excluded.
The microvasculature in the deep ONH and peripapillary area was evaluated using OCTA at 1 day before surgery and 3 months postoperatively. Swept-source OCT scanning of the ONH and measurement of IOP were performed at the time of OCTA.